• slide_obamacare_greaterthan

  • slide_prepvideos

  • Slideshow_hivhealthreform

  • Slideshow_prep

  • Slideshow_hepatitisrisk

Covered California staff recommends capping specialty prescription drug costs


Project Inform applauds the recent recommendation by Covered California staff to cap specialty prescription drug costs at $250 per drug per month for 2016 Covered California Silver, Gold and Platinum level plans. The recommendation will be made Thursday, May 21 at the Covered California Board meeting….Read More

As Project Inform enters its 30 years of service …


Dear Friends — As we enter our 30th year of service to the community. I write to share with you the immense pride I have in the accomplishments of Project Inform. I also write to ask if you will make a gift in support of Project Inform’s lifesaving…Read More

CalHEP recommends nearly $9 million of hepatitis C health care assistance for Californians in next year’s state budget


The unchecked spread of hepatitis C infection threatens the public health and economic welfare of the State of California. There are an estimated 750,000 Californians living with the hepatitis C virus (HCV)[i], and most do not know it[ii]. Untreated HCV can cause, among other conditions, cirrhosis…Read More

VIDEO: How San Francisco plans to ‘get to zero’ new infections of HIV


Project Inform is on the steering committee for this effort to bring new HIV infections to zero, along with zero deaths and zero stigma. Watch this PBS video for more information.

FDA Safety Warning: Potentially Serious Complication between Sofosbuvir and Amiodarone


The U.S. Food and Drug Administration (FDA) has issued a warning about a potentially fatal interaction between the hepatitis C drug sofosbuvir (brand name Sovaldi) and the antiarrhythmic drug amiodarone following the death of one patient and the placement of three others on a pacemaker to…Read More

CROI2015: New “Kick and Kill” HIV cure drug (TLR7 agonist) from Gilead shows promise


A new type of drug, called a toll-like receptor 7 (TLR7) agonist, was able to activate HIV-infected CD4 cells from HIV-positive donors on antiretroviral therapy (ART), leading to the release and replication of virus, according to a presentation at the 2015 Conference on Retroviruses and Opportunistic…Read More

CROI2015: Financial incentives don’t increase case linkage or viral suppression


A large study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle found that offering gift cards to people to reward them for getting into HIV care after testing positive or for getting their viral loads suppressed doesn’t work better than the…Read More